Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

As consumer-facing artificial intelligence tools become more accessible, some patients are increasingly turning to platforms such as ChatGPT for 

 support. This trend raises ethical, clinical, and safety considerations for psychiatrists navigating conversations with patients who may be using AI in place of, or alongside, traditional psychotherapy.

In this Q&A, Dominic Sisti, PhD, from Penn Medicine, discusses access gaps driving adoption, potential benefits, safety concerns, and the guardrails needed for responsible integration of AI into mental health care.

Watch the full feature on the benefits and dangers of AI in psychiatry, featuring Sisti and practicing psychiatrists 

From an ethics standpoint, how should clinicians interpret the growing trend of patients using tools like ChatGPT as a form of informal psychotherapy?

 It's important that clinicians recognize that the prolific use of general-purpose AI for psychotherapy is a sign that there just really isn't enough access to mental health care. People are turning to these tools because they can't get appointments with psychotherapists, or if their insurance policies don't cover the costs. AI is a very easy, convenient solution when someone feels like they need to talk to someone.

Unfortunately, these…AI platforms aren't really trained to treat people in a way like a psychiatrist might, and so there's very important questions around whether they are safe. First off, how would these AI platforms [respond] to a patient who is indicating they have suicidal ideation or behavior?

There's a lot that needs to be worked out still, but I am actually optimistic that AI can provide a level of support to people who otherwise don't have access to mental health care. It's just that these…AI platforms aren't designed for that. There are platforms now that have been trained and are being designed with this in mind, and they seem to be safer; we'll see.

What point does AI-generated mental health guidance cross the threshold from information into something that resembles clinical care?

 If the AI is pushing back suggestions about medications, about psychotherapy, modalities, etc, it might cross that line. I could see an environment that is HIPAA compliant, where the AI has been trained to provide an elevated level of screening, or even some therapeutic modality, could work well.

Right now, the general AIs don't really have guardrails in place, as far as I know, but there are ones that are… being developed by researchers and psychiatrists…who are trying to train up these platforms to respond appropriately and with evidence-based suggestions. I do believe, however, there really should be a human in the loop on all these types of suggestions so that we can be sure that the individual who's using the platform is getting good information.

What are some examples of these guardrails that are in research?

 For example, figuring out ways to redirect a person who may have suicidal ideation or behavior to appropriate resources. How can we design AIs to recognize that elevated risk and prompt the user to reach out to a loved one, or to call a Crisis Text Line?

There's no real regulatory framework around how these guardrails should be put in place. We need to have [an] age restriction….so that kids aren't in there talking about their own mental health challenges and maybe suicidal behaviors without someone being notified of that.

How should clinicians respond when patients disclose they are following advice generated by AI systems?

 I think in a non-judgmental way. I do think that these platforms offer patients another outlet for processing emotions, and depending on the severity level, it might be perfectly appropriate that they're using the platform, or it might be helpful. It really depends on the case.

If a patient shows up and says, “I've been using ChatGPT exclusively, and it's told me everything I do is right,”…there's probably some counseling that needs to happen there. I do think that when patients have experience with… human psychotherapy…an AI agent could actually add a little bit of another perspective because the patient really understands that it's a machine.

What are the most pressing ethical risks associated with patients using AI as a therapist, particularly for individuals with serious mental illness?

 We're just learning now about all the different potential risks to patients who have mental disorders such as schizophrenia, bipolar disorder, or depression. There's been an uptick in what's been called AI-induced psychosis. I think that there is the risk of a patient… having dangerous thoughts and behaviors, and the AI doesn't actually respond correctly, then the AI might actually offer suggestions for killing oneself. We've seen that already.

How should clinicians counsel patients about privacy risk when using consumer-facing AI tools for mental health discussions?

People using them [must be] aware that their data is not really secure. If they're uploading medical information or saying things that are super personal, all those chats can be discovered. If it's a HIPAA-compliant agent, things are a little bit better in terms of privacy.

And what are the most significant gaps in current regulation when it comes to AI and psychiatry?

 If you prompt the AI the right way, you can actually get it to tell you methods of suicide, which should be impossible. In this context, if you're a scholar and you're trying to study suicide, or you're [a] suicidologist, that's different. We need AIs to be able to distinguish between requests for scholarly information versus requests for someone who's really desperate and is looking for that information to use.

What recommendations do you think should be in place?

There’s ways that you can infer age without even asking for age. Being able to figure out if it's a child or a minor and adjusting the chat to an appropriate level, then quickly bringing a human [in] the loop, is critical.

If you could establish one guiding principle for clinicians navigating AI in psychiatry today, what would it be?

If a psychiatrist is working with a patient who is using AI, the guiding principle…is the principle of beneficence. This is one of the four principles of Biomedical Ethics, which is essentially a crystallization of the Hippocratic oath to do no harm, to try to do good.

If the clinician thinks that the AI is adding value to the treatment, then maybe supplementary therapy using an AI seems okay. Those are the questions that will be answered as we learn more about the safety and efficacy, and hopefully, these platforms can be designed in a way that they do add value and are safe and effective.

Articles

Sisti discusses ethics, safety, and guardrails as patients use ChatGPT for mental health support and clinicians navigate AI’s role in psychiatry.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

AI in Psychiatry Raises Ethics Questions With Dominic Sisti, PhD

Aaron Troy, MD, MPH, is a clinical research fellow in cardiovascular medicine at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center.

Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH

The ABCs of Cardiovascular Disease (CVD) Prevention, initially published in 2001 as a method to identify and address the various aspects of prevention for patients and clinicians, has recently undergone a major update.

American College of Cardiology (ACC) Scientific Sessions 2026

 editorial team met with Aaron Troy, MD, MPH, clinical research fellow in cardiovascular medicine at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, to discuss the recent changes and how they can impact 1 of the most prominent disease states in the US.

“This is a profound opportunity for everyone in the United States across cardiology subspecialties and internal medicine to really reconsider and optimize our cardiovascular disease prevention for patients overall,” Troy told 

 in an exclusive interview. “That’s really the impetus for the updated ABCs. They’re a framework for summarizing the core tenets of preventive cardiology.”

Currently, the ABCs of CVD Prevention are broken into 6 main letters, which are in turn composed of 2 recommendations each. The full list is as follows:

Assess CVD Risk (Life’s Essential 8, PREVENT, risk enhancers)

Antiplatelets (consider in high-risk primary prevention, prescribe for secondary)

Blood Pressure (target <130/80 mmHg, close follow-up & home monitoring)

Body Fat (measure waist, assess complications, target >5% weight loss)

Cholesterol (assess regularly in all life stages, consider combination therapy)

Diet (Mediterranean, DASH, plant-based, calorie deficit)

Diabetes and CKM Syndrome (screen with A1c, eGFR, UACR, target CKM with SGLT2i, GLP-1 RAs)

Exercise (>150 minutes/week, resistance training >2x/week)

Extend Healthspan (assess physical & cognitive function, multidisciplinary care, cardiac rehab)

 (Identify & optimize in Stage B HF, GDMT in Stage C HF)

 (anticoagulate for CHA2DS2-VASc ≥2-3, consider early rhythm control)

The new document emphasizes the importance of the PREVENT equations, which were formulated using a larger and more contemporary population than the widely utilized Pooled Cohort Equations (PCEs). The recalibration of these equations resulted in a 10-year risk estimate roughly 40-50% lower than the PCE – this highlights the need for personalized approaches to avoid undertreating patients.

Additionally, Life’s Essential 8 once again takes center stage in CVD, with the health behavior checklist encompassing almost every avenue by which CVD can occur. Patients are encouraged to improve their sleep schedules, exercise regimens, and diet, with specific, targeted goals provided within the framework. Additionally, lipids, glucose, and blood pressure are spotlighted as major contributors to CVD, leading to greater emphasis on their reduction.

Notably, the new ABCs also include the traditionally disease-focused areas of heart failure and atrial fibrillation. The document recommends that clinicians identify patients with stage B heart failure and prevent their progression to stage C, as well as treating stage C heart failure to prevent further hospitalizations and mortality. Atrial fibrillation, meanwhile, is the most common cardiac arrythmia in the US despite modifiable risk factors – the new ABCs encourage clinicians to optimize these risk factors and prevent the increased morbidity and mortality associated with the condition.

Troy also discussed the importance of the updated framework, noting the shortcomings currently facing cardiovascular care in the US.

“The time has come for a new and improved – and sort of streamlined – framework to optimize cardiovascular disease prevention,” Troy said. “The levels of 

 awareness, hypertension control, cholesterol control, really everything is suboptimal on a national level, and with the obesity epidemic driving cardiovascular-kidney-metabolic disease and population aging, the patient landscape is evolving.”

Editors’ Note: Troy reports a disclosure with the American Academy of Home Care Medicine.

Goren LR, Peng AW, Razavi AC, Blaha MJ, Blumenthal RS, Troy AL. The ABCs of Cardiovascular Disease Prevention: Communicating What We Know in 2026. 

American Journal of Preventive Cardiology

. Published online March 20, 2026:101570. 

Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: Updating and enhancing the American Heart Association’s construct of Cardiovascular Health: A presidential advisory from the American Heart Association. 

Videos

Troy discusses the recent changes to the ABCs of CVD, highlighting an increased focus on lifestyle interventions and the management of risk factors.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Arrhythmia

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Expanding Dialysis Access: Policy, Variation, and the Role of Peritoneal Dialysis

The issue of global access to home dialysis is a multilayered problem requiring a multifaceted solution, including policy changes, reimbursement systems, and technological innovation, according to experts from the International Home Dialysis Consortium (IHDC).

HCPLive sat down with Simon Davies, MD, a consultant nephrologist at the University Hospital of North Midlands and professor of nephrology and dialysis medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University, who presented the discussion at the World Congress of Nephrology (WCN) in Yokohama, Japan.

Significant variation in dialysis modality use persists across regions, despite ongoing efforts to expand home-based care options. As healthcare systems continue to explore ways to expand dialysis access, questions remain about how best to increase uptake of home-based modalities such as peritoneal dialysis (PD) and home hemodialysis (HHD).

On the policy front, Davies discusses the implementation of a PD-first policy, where patients are initiated on peritoneal dialysis before transitioning to other modalities. This approach has been used as a tool for healthcare expansion, and has been particularly successful in Hong Kong, which has the highest rates of home dialysis.

The greatest risk with this approach is public perception, Davies explains, where PD use among previously disadvantaged populations can lead to perceptions that it is a lower-quality therapy, particularly when wealthier patients receive in-center hemodialysis. This is primarily a social conundrum, as outcomes data show similar results between modalities. Still, patients strongly value having choice in dialysis modality.

To mitigate this, a more flexible PD-preferred approach may be used, where the system encourages PD but does not require it as a first option. Davies gives an example of where this has worked in Mexico, which preserves patient choice while supporting, rather than mandating, home dialysis.

“Most countries are reluctant to go down those sorts of routes. They would rather maintain the free choices available for dialysis,” explained Davies. “By and large, that’s what I would say is the best approach that we should be going for, supporting people to do home dialysis when they want to do it.”

Locating The Real Problem In Rural Communities

 where Davies discussed the global gaps in at-home dialysis, including system-level barriers, provider biases, and policy misalignment.

Brown EA, Jha V, Bavanandan S, et al. International Home Dialysis Consortium: Declaration Advocating for the Promotion of Home Dialysis Globally. 

https://doi.org/10.1016/j.ekir.2025.03.012

Hillenbrand A. HCPLive. Published 2026. Accessed April 10, 2026. https://www.hcplive.com/view/gaps-in-home-dialysis-access-persist-globally-with-simon-davies-md

Davies explains the future of at-home dialysis access, including policy changes and technological innovation. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University

Robert Gish, MD, is the Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania. He is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University. In addition, he is the Medical Director of the American Pacific Health Foundation.

Saul Karpen, MD, PhD, is is the inaugural chief scientific officer for the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, Richmond, Va., where he is a professor of internal medicine and adjunct professor in pediatric medicine at the VCU School of Medicine. He holds the Phillip B. Hylemon Endowed Chair of Medicine and Microbiology and is a pediatric hepatologist at the VCU Children’s Hospital of Richmond. He is also the president of AASLD.

Genetic Testing in Liver Disease: Interpreting Results and Clinical Impact

As genetic testing becomes more integrated into hepatology, clinicians are increasingly faced with challenges regarding how to interpret results and incorporate them into a broader diagnostic framework. In this segment of 

Liver Lineup: Updates & Unfiltered Insights

, guests Robert Gish, MD, and Saul Karpen, MD, PhD, explore the complexities of genetic interpretation, the evolving role of multidisciplinary evaluation, and how traditional tools like biopsy remain essential in the era of genomics.

Genetic panels often require clinical correlation, especially when results return as variants of uncertain significance

“Synergistic heterozygosity” may explain disease when multiple variants are present rather than a single mutation

Genetic testing can uncover rare, actionable diagnoses such as lysosomal acid lipase deficiency

Liver biopsy remains critical when genetic results are inconclusive or do not fully explain the clinical picture

Referral to genetics is most useful for targeted cases, including rare diseases and reproductive counseling

Whole-exome sequencing may be needed when standard panels are unrevealing but suspicion for genetic disease remains

Gish highlighted the limitations of relying solely on genetics, noting that referrals to major academic centers for additional interpretation often yield limited new insights unless more expansive approaches, such as whole-exome or whole-genome sequencing, are pursued. Instead, he has shifted toward a more selective and clinically driven use of genetic consultation, reserving referrals for targeted scenarios such as rare diagnoses, complex counseling questions, or reproductive planning.

At the same time, genetic testing can uncover unexpected and actionable findings. Gish described a patient with atypical cholestatic liver disease who was ultimately diagnosed with lysosomal acid lipase deficiency, a rare condition that would have been difficult to identify without genetic evaluation. In another case, identification of dual heterozygous variants helped explain overlapping pulmonary and hepatic disease, reinforcing the concept that multiple genetic factors can interact to shape clinical presentation.

This concept, referred to as “synergistic heterozygosity,” is gaining increasing recognition in hepatology. Rather than a single causative mutation, patients may harbor multiple variants that collectively contribute to disease. This paradigm challenges traditional binary thinking and underscores the importance of interpreting genetic results in clinical context.

A major continued barrier to adoption, however, is the interpretation of variants of uncertain significance (VUS). Gish argued that this terminology can be misleading and counterproductive, preferring instead a more pragmatic approach that emphasizes clinical correlation. For hepatologists, this means integrating genetic findings with other core elements of liver disease evaluation, including laboratory testing, imaging, and histology.

Indeed, both Gish and Karpen emphasized that genetic testing should complement established diagnostic tools rather than replace them. Liver biopsy, in particular, continues to play a critical role, especially when genetic findings are inconclusive. Histologic evidence of cholangiopathy or other structural abnormalities can help validate the clinical relevance of a genetic variant and, in some cases, contribute to its reclassification as pathogenic.

Karpen also highlighted the dynamic nature of genetic interpretation. A result considered inconclusive today may be better understood in the future as additional data emerge. In some cases, reanalysis of prior genetic testing has led to new diagnoses, reflecting the rapidly evolving knowledge base in genomics.

Editors’ note: Relevant disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for Karpen include Mirum and Ipsen. Relevant disclosures for Gish include Abbott, AbbVie, Aligos, Altimmune, Arrowhead, AstraZeneca, Corcept, Genentech, Gilead Sciences, GSK, Intercept, Janssen, Merck, Perspectum, Pfizer, and others.

Experts discuss interpreting genetic testing in liver disease, the role of biopsy, and how to integrate variants into clinical decision-making.

Hepatology

Putting the Pieces Together: Genetic Testing, Biopsy, and Clinical Judgment

Nicole Chase, MD, is a board-certified allergist/immunologist at St. Paul Allergy Asthma, Minneapolis VA Health Care System (part-time), and an associate professor of medicine at the University of Minnesota Medical School.

Why FDA Removed the Age Limit for Epinephrine Nasal Spray

 removal of the minimum age requirement for the 1 mg 

 aligns the product with weight-based dosing used across other epinephrine formulations, such as autoinjectors. The updated label, announced by ARS Pharmaceuticals on March 27, 2026, now allows use in any patient weighing ≥ 33 pounds.

“The drug works in patients regardless of the age requirement,” Nicole Chase, MD, an allergist/immunologist at St. Paul Allergy & Asthma and associate professor of medicine at the University of Minnesota Medical School, told 

. “It's really a weight-based drug, and… it's kind of strange that [the age requirement] was there in the first place.”

Chase noted the decision did not rely on dedicated studies in children younger than 4 years old. Instead, regulators reviewed available pharmacokinetic and pharmacodynamic data and applied an approach similar to injectable epinephrine, which has historically been dosed according to weight.

With expanded labeling, Chase emphasized clinician-led education to minimize adverse effects, particularly during initial use. She recommends hands-on training with demonstration devices during clinic visits.

Proper technique, particularly avoiding sniffing during delivery, may improve tolerability. Chase typically recommends observing patients for approximately 1 hour after administration to monitor response and potential reactions.

If symptoms persist, Chase advises administering a second dose in the same nostril, reflecting study findings showing improved response with this approach. She also recommends emergency evaluation if repeat dosing is required.

Insurance coverage and cost remain considerations, though access programs may help reduce out-of-pocket expenses. Chase described a program that uses a third party to get an epinephrine nasal spray. Overall, she said that the epinephrine nasal spray is doing a job in getting into patients’ hands.

“I’m so glad that the FDA has decided to streamline things,” Chase said. “We already struggle as clinicians…with reassuring parents that epi is safe…effective…[and] the number 1 therapy for a severe allergic reaction like anaphylaxis. Anytime the FDA can remove barriers to making people worry that, ‘oh, is this different somehow? Is this not as good?’ I think that always helps our cause as prescribers to really let them focus on if you even think you need it, just go ahead and take it. Removing that age requirement really just allows us to prescribe like we've been prescribing for other epinephrine devices.”

Part 1 of the interview with Chase can be watched

Relevant disclosures for Chase include GENZYME CORPORATION, Regeneron Healthcare Solutions, Incyte Corporation, Novartis Pharmaceuticals, Blueprint Medicines Corporation, Genentech USA, and AstraZeneca Pharmaceuticals.

ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label. GlobeNewswire News Room. Published March 27, 2026. Accessed March 27, 2026. 

https://www.globenewswire.com/news-release/2026/03/27/3263722/0/en/ARS-Pharmaceuticals-Receives-FDA-Approval-to-Remove-Age-Requirement-From-neffy-1-mg-epinephrine-nasal-spray-Label.html

Campbell P. FDA Removes Age Requirement for Epinephrine Nasal Spray, Now Based on Weight Alone. HCPLive. March 27, 2026. Accessed April 9, 2026. 

https://www.hcplive.com/view/fda-removes-age-requirement-for-epinephrine-nasal-spray-now-based-on-weight-alone

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Weight-Based Dosing Informs Age Removal for Epinephrine Nasal Spray, With Nicole Chase, MD

Alberico Catapano, PhD, is the research director and head of the laboratory of lipoproteins and atherosclerosis and of the lipid clinic at MultiMedica IRCCS.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Dyslipidemia

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Genetic Panels in Hepatology: Identifying the Right Patients

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Biologics Across the Airway: Selection, Remission Goals, and Real-World Barriers

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.


FDA Removes Age Restriction for Epinephrine Nasal Spray, With Nicole Chase, MD

Anjali Vaidya, MD, is the director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program and the Pulmonary Hypertension Fellowship at Temple University Hospital and a professor of medicine at Temple University

Vaidya discusses the 2022 pulmonary arterial hypertension guidelines and how they can be made more accessible for clinicians just entering the field.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

The Mechanics Behind PAH Diagnosis and Management, With Anjali Vaidya, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Hematology

Q1 2026 Recap: Hematology News and Updates

Catch up on nephrology headlines you missed from Q1 2026.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA News

Q1 2026 Recap: Nephrology News and Updates

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on FDA decisions, new GLP-1 agonists, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Q1 2026 Recap: Endocrinology News and Updates

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.

Latest News

AI in Psychiatry Raises Ethics Questions With Dominic Sisti, PhD

Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH

Expanding Dialysis Access: Policy, Variation, and the Role of Peritoneal Dialysis

Putting the Pieces Together: Genetic Testing, Biopsy, and Clinical Judgment

Weight-Based Dosing Informs Age Removal for Epinephrine Nasal Spray, With Nicole Chase, MD